RecruitingPhase 1Phase 2NCT06903377

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Enrollment

50 participants

Start Date

May 23, 2025

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of ZG005 and gecacitinib — two investigational drugs — in patients with advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed or has spread. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed locally advanced or metastatic non-small cell lung cancer (squamous or non-squamous type) - Your cancer is not suitable for curative treatment - You have given informed consent **You may NOT be eligible if...** - Imaging shows cancer has spread to the brain or spinal cord (CNS metastases) - You have had another cancer diagnosis within the past 5 years - Your doctor determines you are not a suitable candidate for other medical reasons Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.